CS2164 exerts an antitumor effect against human Non-Hodgkin's lymphomas in vitro and in vivo

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations

Medicine, Oncology, Pharmacotherapy +11

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Thomas E. Witzig, Julie M. Vose, Pier Luigi Zinzani et al. · Annals of Oncology · 2011 · 393 citations · Full text

Medicine, Oncology, Pharmacology +13

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

Marinus H. J. van Oers, M. van Glabbeke, L. Giurgea et al. · Journal of Clinical Oncology · 2010 · 337 citations

Medicine, Oncology, Pharmacotherapy +15

CENP-A is phosphorylated by Aurora B kinase and plays an unexpected role in completion of cytokinesis

Samantha G. Zeitlin, Richard D. Shelby, Kevin F. Sullivan · The Journal of Cell Biology · 2001 · 334 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Lida Kalmanti, Michael Lauseker, M. C. Muller et al. · Leukemia · 2015 · 274 citations

Medicine, Pharmacology, Pharmacotherapy +5